Sign in or create an account to add this stock to your watchlist.
About Minerva Neurosciences (NASDAQ:NERV)
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company' preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NERV
CUSIPN/A
Phone617-600-7373
Debt
Debt-to-Equity RatioN/A
Current Ratio15.85
Quick Ratio15.85
Price-To-Earnings
Trailing P/E Ratio-8.29
Forward P/E Ratio-6.13
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.13 per share
Price / Book2.86
Profitability
EPS (Most Recent Fiscal Year)($1.08)
Net Income$-31,520,000.00
Net MarginsN/A
Return on Equity-35.48%
Return on Assets-25.14%
Miscellaneous
Employees12
Outstanding Shares38,750,000
Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions
What is Minerva Neurosciences' stock symbol?
Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."
How were Minerva Neurosciences' earnings last quarter?
Minerva Neurosciences Inc (NASDAQ:NERV) released its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.04. View Minerva Neurosciences' Earnings History.
What price target have analysts set for NERV?
2 brokers have issued 1 year price objectives for Minerva Neurosciences' stock. Their forecasts range from $11.00 to $20.00. On average, they anticipate Minerva Neurosciences' share price to reach $15.50 in the next year. View Analyst Ratings for Minerva Neurosciences.
Who are some of Minerva Neurosciences' key competitors?
Some companies that are related to Minerva Neurosciences include Radius Health (RDUS), Amneal Pharmaceuticals (AMRX), Biohaven Pharmaceutical (BHVN), Myovant Sciences (MYOV), TherapeuticsMD (TXMD), Theravance Biopharma (TBPH), Epizyme (EPZM), WAVE Life Sciences (WVE), Uniqure (QURE), Intra-Cellular Therapies (ITCI), Immuron (IMRN), Retrophin (RTRX), Revance Therapeutics (RVNC), Mirati Therapeutics (MRTX) and Apellis Pharmaceuticals (APLS).
Who are Minerva Neurosciences' key executives?
Minerva Neurosciences' management team includes the folowing people:
- Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 57)
- Mr. Geoffrey Robin Race FCMA, MBA, Exec. VP, CFO & Chief Bus. Officer (Age 57)
- Mr. Joseph Reilly, Sr. VP & COO (Age 43)
- Mr. Richard Russell, Pres
- Mr. Frederick W. Ahlholm CPA, Sr. VP & Chief Accounting Officer (Age 52)
Has Minerva Neurosciences been receiving favorable news coverage?
Media coverage about NERV stock has been trending somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Minerva Neurosciences earned a coverage optimism score of 0.23 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.35 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Minerva Neurosciences' major shareholders?
Minerva Neurosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Highland Capital Management LP (5.80%), BlackRock Inc. (5.06%), Millennium Management LLC (2.31%), JPMorgan Chase & Co. (1.55%), Northern Trust Corp (0.78%) and Artal Group S.A. (0.77%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Marc D Beer, Mark S Levine, Remy Luthringer and Venture Associates L Index III. View Institutional Ownership Trends for Minerva Neurosciences.
Which major investors are selling Minerva Neurosciences stock?
NERV stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BlackRock Inc. and Northern Trust Corp. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly and Remy Luthringer. View Insider Buying and Selling for Minerva Neurosciences.
Which major investors are buying Minerva Neurosciences stock?
NERV stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, Highland Capital Management LP, Artal Group S.A. and Alps Advisors Inc.. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer and Marc D Beer. View Insider Buying and Selling for Minerva Neurosciences.
How do I buy shares of Minerva Neurosciences?
Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Minerva Neurosciences' stock price today?
One share of NERV stock can currently be purchased for approximately $8.95.
How big of a company is Minerva Neurosciences?
Minerva Neurosciences has a market capitalization of $331.31 million. The biopharmaceutical company earns $-31,520,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis. Minerva Neurosciences employs 12 workers across the globe.
How can I contact Minerva Neurosciences?
Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]
MarketBeat Community Rating for Minerva Neurosciences (NERV)
MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe NERV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NERV will underperform the S&P 500 over the long term. You may vote once every thirty days.
Minerva Neurosciences (NASDAQ:NERV) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Minerva Neurosciences in the last 12 months. Their average twelve-month price target is $15.50, suggesting that the stock has a possible upside of 73.18%. The high price target for NERV is $20.00 and the low price target for NERV is $11.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $15.50 | $15.50 | $16.00 | $16.00 |
| Price Target Upside: | 73.18% upside | 156.20% upside | 164.46% upside | 164.46% upside |
Minerva Neurosciences (NASDAQ:NERV) Consensus Price Target History
Minerva Neurosciences (NASDAQ:NERV) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/1/2017 | Citigroup | Initiated Coverage | Buy | $11.00 | High |  |
| 6/1/2017 | JMP Securities | Reiterated Rating | Outperform | $17.00 ➝ $20.00 | Low | |
| 3/6/2017 | Jefferies Group | Initiated Coverage | Buy ➝ Buy | $17.00 | N/A | |
(Data available from 5/25/2016 forward)
Minerva Neurosciences (NASDAQ:NERV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Minerva Neurosciences (NASDAQ NERV) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 70.59%
Minerva Neurosciences (NASDAQ NERV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/14/2017 | Frederick W Ahlholm | SVP | Sell | 1,661 | $5.80 | $9,633.80 | 10,000 | |
| 12/14/2017 | Geoff Race | CFO | Sell | 5,829 | $5.79 | $33,749.91 | 197,698 | |
| 12/14/2017 | Joseph H Reilly | COO | Sell | 2,906 | $5.80 | $16,854.80 | 17,083 | |
| 12/14/2017 | Remy Luthringer | CEO | Sell | 2,194 | $5.85 | $12,834.90 | 18,750 | |
| 3/20/2017 | Marc D Beer | Director | Buy | 50,000 | $8.12 | $406,000.00 | 25,000 | |
| 2/6/2017 | Geoff Race | CFO | Sell | 21,450 | $11.02 | $236,379.00 | 186,890 | |
| 2/6/2017 | Remy Luthringer | CEO | Sell | 34,281 | $11.02 | $377,776.62 | 32,096 | |
| 1/11/2017 | Joseph H Reilly | COO | Sell | 1,600 | $12.03 | $19,248.00 | 9,933 | |
| 1/4/2017 | Mark S Levine | SVP | Sell | 17,500 | $12.00 | $210,000.00 | 17,250 | |
| 12/27/2016 | Frederick W Ahlholm | SVP | Sell | 17,000 | $12.51 | $212,670.00 | 22,000 | |
| 8/10/2016 | Venture Associates L Index III | Major Shareholder | Sell | 1,000,000 | $10.00 | $10,000,000.00 | | |
| 6/21/2016 | David Kupfer | Director | Buy | 55,635 | $10.84 | $603,083.40 | 209,188 | |
| 3/17/2016 | David Kupfer | Director | Buy | 181,488 | $5.51 | $999,998.88 | 181,488 | |
| 3/18/2015 | Care Capital Iii Llc | Major Shareholder | Sell | 1,206,700 | $5.75 | $6,938,525.00 | | |
| 3/18/2015 | Rubertis Francesco De | Director | Buy | 202,634 | $4.81 | $974,669.54 | | |
| 3/13/2015 | & Johnson Johnson | Major Shareholder | Buy | 607,903 | $4.81 | $2,924,013.43 | | |
| 1/26/2015 | Care Capital Iii Llc | Major Shareholder | Sell | 482,112 | $5.11 | $2,463,592.32 | | |
| 1/8/2015 | Care Capital Iii Llc | Major Shareholder | Sell | 531,808 | $7.38 | $3,924,743.04 | | |
| 7/7/2014 | Care Capital Iii Llc | Major Shareholder | Buy | 737,500 | $6.00 | $4,425,000.00 | | |
| 7/7/2014 | Michele Ollier | Director | Buy | 1,620,833 | $6.00 | $9,724,998.00 | | |
| 7/1/2014 | Coelho Rogerio Vivaldi | CEO | Buy | 41,667 | $6.00 | $250,002.00 | | |
| 7/1/2014 | Frederick W Ahlholm | CAO | Buy | 10,000 | $6.00 | $60,000.00 | | |
| 7/1/2014 | Geoff Race | CFO | Buy | 33,333 | $6.00 | $199,998.00 | | |
| 7/1/2014 | Heek G Jan Van | Director | Buy | 3,333 | $6.00 | $19,998.00 | | |
| 7/1/2014 | Joseph H Reilly | Insider | Buy | 8,333 | $6.00 | $49,998.00 | | |
(Data available from 1/1/2013 forward)
Minerva Neurosciences (NASDAQ NERV) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Minerva Neurosciences (NERV) & Portola Pharmaceuticals (PTLA) Critical Contrast
www.americanbankingnews.com - May 23 at 11:33 AM |
| Zacks: Brokerages Anticipate Minerva Neurosciences (NERV) Will Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - May 18 at 3:19 PM |
| ValuEngine Upgrades Minerva Neurosciences (NERV) to Sell
www.americanbankingnews.com - May 17 at 10:23 PM |
 | Minerva Neurosciences' roluperidone shows treatment effect in schizophrenia patients; shares ahead 13% premarket
seekingalpha.com - May 17 at 6:38 PM |
 | Minerva Neurosciences shares rise 5% on trial results for schizophrenia drug
finance.yahoo.com - May 17 at 6:38 PM |
| Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symp...
finance.yahoo.com - May 17 at 8:22 AM |
| Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia
finance.yahoo.com - May 17 at 8:22 AM |
| Minerva Neurosciences (NERV) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 15 at 11:50 AM |
| Minerva Neurosciences (NERV) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - May 4 at 8:15 PM |
| Edited Transcript of NERV earnings conference call or presentation 3-May-18 12:30pm GMT
finance.yahoo.com - May 4 at 8:18 AM |
| Minerva Neurosciences' (NERV) CEO Dr. Remy Luthringer on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 5:24 PM |
| Minerva Neurosciences: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 5:24 PM |
| Minerva Neurosciences (NERV) Raised to Sell at ValuEngine
www.americanbankingnews.com - May 3 at 11:50 AM |
 | BRIEF-Minerva Neurosciences Reports Q1 Loss Per Share $0.32
www.reuters.com - May 3 at 8:17 AM |
| Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates
finance.yahoo.com - May 3 at 8:17 AM |
| -$0.30 Earnings Per Share Expected for Minerva Neurosciences (NERV) This Quarter
www.americanbankingnews.com - May 1 at 1:06 AM |
| Minerva Neurosciences (NERV) Downgraded by ValuEngine
www.americanbankingnews.com - April 27 at 10:20 PM |
| Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018
finance.yahoo.com - April 26 at 5:16 PM |
| Minerva Neurosciences (NERV) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 16 at 8:06 PM |
| Minerva Neurosciences (NERV) Expected to Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - April 14 at 3:17 AM |
| Zacks Investment Research Upgrades Minerva Neurosciences (NERV) to "Buy"
www.americanbankingnews.com - April 12 at 3:27 PM |
| BRIEF-Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive Disorder
www.reuters.com - April 9 at 5:21 PM |
| Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
finance.yahoo.com - April 9 at 5:21 PM |
| Minerva Neurosciences (NERV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 9 at 2:26 PM |
| Minerva Neurosciences (NERV) Upgraded at BidaskClub
www.americanbankingnews.com - April 6 at 10:46 AM |
| Minerva Neurosciences (NERV) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - April 5 at 1:55 PM |
| Minerva Neurosciences Inc (NERV) Expected to Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - March 28 at 3:08 AM |
 | Will Minerva Neurosciences (NERV) Continue to Surge Higher? March 23, 2018
www.zacks.com - March 24 at 5:15 PM |
| Will Minerva Neurosciences (NERV) Continue to Surge Higher?
finance.yahoo.com - March 23 at 5:42 PM |
| Minerva Neurosciences (NERV) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 17 at 12:04 PM |
 | Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday ... - GlobeNewswire (press release)
globenewswire.com - March 16 at 8:21 AM |
| Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22
finance.yahoo.com - March 15 at 6:11 PM |
| Brokers Offer Predictions for Minerva Neurosciences Inc's FY2018 Earnings (NERV)
www.americanbankingnews.com - March 15 at 9:04 AM |
| Jefferies Group Comments on Minerva Neurosciences Inc's Q1 2018 Earnings (NERV)
www.americanbankingnews.com - March 14 at 7:21 AM |
| Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates - GlobeNewswire (press release)
www.globenewswire.com - March 12 at 6:38 PM |
 | Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and ... - Nasdaq
www.nasdaq.com - March 12 at 6:38 PM |
| Minerva Neurosciences posts 4Q profit
finance.yahoo.com - March 12 at 9:15 AM |
| Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates
finance.yahoo.com - March 12 at 9:15 AM |
| Minerva Neurosciences Inc (NERV) Expected to Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - March 10 at 9:20 PM |
| Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates ... - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:15 AM |
| Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018
finance.yahoo.com - March 5 at 5:49 PM |
| Ascend Capital LLC Has $4.96 Million Stake in Minerva Neurosciences Inc (NERV)
www.americanbankingnews.com - March 1 at 4:42 AM |
| Minerva Neurosciences, Inc (NERV) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 23 at 1:44 AM |
| Zacks: Analysts Anticipate Minerva Neurosciences, Inc (NERV) to Announce -$0.43 Earnings Per Share
www.americanbankingnews.com - February 22 at 5:08 AM |
| Minerva Neurosciences, Inc (NERV) Short Interest Update
www.americanbankingnews.com - February 12 at 4:08 AM |
| TBPH Inks $1Bln Deal, SGMO Hits Yearly High, ANAB Is Back Again
www.nasdaq.com - February 8 at 8:11 AM |
| BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman
www.reuters.com - February 5 at 9:40 AM |
 | Minerva Neurosciences, Inc.: Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director
www.finanznachrichten.de - February 5 at 9:40 AM |
| Minerva Neurosciences (NERV) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - February 4 at 8:40 PM |
| Head-To-Head Comparison: Minerva Neurosciences (NERV) & Its Peers
www.americanbankingnews.com - February 2 at 5:12 PM |
Minerva Neurosciences (NASDAQ:NERV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Minerva Neurosciences (NASDAQ:NERV) Income Statement, Balance Sheet and Cash Flow Statement
Minerva Neurosciences (NASDAQ NERV) Stock Chart for Friday, May, 25, 2018
Loading chart…
